Navigation Links
Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event

Recent clinical studies support the development of DG041 as an effective anti-platelet that does not increase bleeding risk

REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-FirstCall/ -- deCODE genetics today announced progress in the development of DG041, the company's Phase II developmental compound for the prevention of arterial thrombosis. The results of the Phase IIa and clinical pharmacology studies presented today build upon previous findings demonstrating DG041's profile as an anti-platelet compound that deCODE expects will make it possible to block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. There is a large unmet medical need for a drug with these characteristics, with applicability to the prevention of heart attack, stroke and the progression of peripheral artery disease (PAD). Drugs such as Plavix(TM) and aspirin, the current mainstays of oral anti-platelet therapy, significantly increase the risk of bleeding by broadly blocking platelet activity.

Recent advances in deCODE's therapeutic and diagnostics pipeline will be discussed at the company's annual R&D event being held today in Reykjavik. The presentations will be webcast live through the investors page of the company's website at http://www.decode.com, starting at 9am GMT/5am EDT, and will be archived on the site. Among the highlights to be discussed are:

DG041 -- Arterial thrombosis.

DG041 is a novel, first in class antagonist of the EP3 receptor for prostaglandins E2. deCODE initially identified EP3 as a target by isolating variants in the gene encoding the EP3 receptor for prostaglandins E2 (PGE2) that approximately double the risk of PAD, a common and debilitating atherosclerotic condition in which the flow of blood to the legs is progressively constricted. The mechanism through which EP3
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... , HARRISBURG, Pa., Aug. 20 Department of Environmental ... number of West Nile Virus cases has dropped, the threat still ... and make every effort to control mosquitoes and reduce the threat ... number of West Nile cases has substantially decreased in recent years ...
... , , , , ... Stemedica Cell Technologies , Inc. USA, a ... New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") ... mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke. ...
Cached Medicine Technology:DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat 2DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat 3Stemedica Requests Pre-IND Meeting With FDA 2
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of her ... use of his left side. Eating became a difficult task for ... like them enjoy eating again,” said an inventor, from Fayetteville, N.C. ... HALL PLATE (P C H PLATE). , The PATRICIA CAROL HALL ... eat for individuals who suffer from stroke, experience tremors or loss ...
(Date:7/12/2014)... With prom shopping reaching its final ... is ready to showcase its new and trendy apparels. ... evening dresses in its online shop. Additionally, it is ... these elegant gowns. According to the company’s sales manager, ... 26, 2014. , He says, “Now, worldwide clients ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... Utah Valley Entrepreneurial Forum Top 25 ... being bestowed to companies in revenue, and pre-revenue startups. ... with recognition for new ideas as well as companies ... , 25 Under 5 highlights outstanding Utah entrepreneurs and ... 5 years old. Award recipients were recognized at their ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... new funding from the Bill & Melinda Gates Foundation to ... help agency expand services in 11 new countries, ... world,s largest microfinance organizations, today,announced it has received a $24.2 ... will help Opportunity International,s,subsidiary, the Micro Insurance Agency, greatly expand ...
... Quarter 2008 Sees 52 Percent Increase in Sales from Same ... ... Greenway Medical Technologies,Inc., a leading provider of integrated electronic health records ... its second quarter of fiscal 2008, ending,December 31, 2007, were up ...
... announced it will host a webcast and conference call at 10 am,ET on Friday, ... 2007, which ended December 31. Financial,results are scheduled for release after the market closes ... Robert Holster, Chairman and CEO ... Walter Hosp, SVP ...
... more likely to remain depressed than older men, according to ... the February Archives of General Psychiatry. , The Yale ... while depressed than older men, indicating that women live longer ... likelihood of women becoming depressed and remaining depressed, collectively contribute ...
... constructed with soft lithography, should boost research in which ... screen new pharmaceuticals for potential treatment of parasitic infections ... The tools -- an artificial soil device and a ... easily in a human hand -- are detailed in ...
... Alienation Awareness,Organization (PAAO) is beginning the New Year by ... Parental Alienation Awareness Day., Because most people do ... alienation awareness was put forth to help raise,awareness and ... PAAO is to help the public and professionals become,aware ...
Cached Medicine News:Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 2Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 4Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 5Health News:Greenway Medical Technologies Continues Record Setting Growth 2Health News:Greenway Medical Technologies Continues Record Setting Growth 3Health News:Greenway Medical Technologies Continues Record Setting Growth 4Health News:HMS Holdings Corp. Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 2Health News:Older women more susceptible to depression than older men 2Health News:New devices to boost nematode research on neurons and drugs 2Health News:New devices to boost nematode research on neurons and drugs 3Health News:Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: